Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2010 1
2011 1
2014 1
2015 1
2018 1
2019 4
2020 3
2021 3
2022 4
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma.
Matsubara Y, Toriyama K, Kadowaki S, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Masuishi T, Bando H, Ando M, Tajika M, Oze I, Hosoda W, Muro K. Matsubara Y, et al. Among authors: kato k. Esophagus. 2023 Jul;20(3):524-532. doi: 10.1007/s10388-022-00978-7. Epub 2023 Jan 3. Esophagus. 2023. PMID: 36595124
Genomic Landscape of Primary Tumor Site and Clinical Outcome for Patients with Metastatic Colorectal Cancer Receiving Standard-of-Care Chemotherapy.
Mizukami T, Takahashi M, Sunakawa Y, Yuki S, Kagawa Y, Takashima A, Kato K, Hara H, Denda T, Yamamoto Y, Shiozawa M, Oki E, Okamoto W, Yoshino T, Eguchi Nakajima T. Mizukami T, et al. Among authors: kato k. Target Oncol. 2022 May;17(3):343-353. doi: 10.1007/s11523-022-00880-3. Epub 2022 May 7. Target Oncol. 2022. PMID: 35524872
Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer.
Matsubara Y, Masuishi T, Ogata T, Nakazawa T, Kato K, Nozawa K, Narita Y, Honda K, Bando H, Taniguchi H, Kadowaki S, Ando M, Tajika M, Muro K. Matsubara Y, et al. Among authors: kato k. J Cancer Res Clin Oncol. 2023 Mar;149(3):1123-1129. doi: 10.1007/s00432-022-03979-2. Epub 2022 Mar 22. J Cancer Res Clin Oncol. 2023. PMID: 35314873 Clinical Trial.
21 results